MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./280/0.1/21.03.25 Share Price

Warrant

DE000MG0Y1L3

Market Closed - Börse Stuttgart 19:52:16 25/06/2024 BST
0.58 EUR +5.45% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./280/0.1/21.03.25
Current month+45.00%
1 month+48.72%
Date Price Change
25/06/24 0.58 +5.45%
24/06/24 0.55 -9.84%
21/06/24 0.61 -3.17%
20/06/24 0.63 +26.00%
19/06/24 0.5 -5.66%

Delayed Quote Börse Stuttgart

Last update June 25, 2024 at 07:52 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0Y1L
ISINDE000MG0Y1L3
Date issued 27/03/2024
Strike 280 $
Maturity 21/03/2025 (269 Days)
Parity 10 : 1
Emission price 0.82
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.12
Lowest since issue 0.31
Spread 0.03
Spread %4.92%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
233.9 USD
Average target price
279.2 USD
Spread / Average Target
+19.38%
Consensus